

Amendments to the Claims:

No amendments to the claims are made herein. This listing of claims is for the Examiner's convenience and will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-5 (canceled).

Claim ~~6~~¹ (previously presented): A method of identifying a FK506 analog that stimulates nerve cell growth, the method comprising:
screening a plurality of FK506 analogs for binding to FKBP-12;
selecting a FK506 analog that has an apparent K_d for FKBP-12 of greater than 100 μ M; and
assaying the FK506 analog for activity in promoting nerve cell growth, thereby identifying a FK506 analog that stimulates nerve cell growth.

Claim ~~7~~² (previously presented): The method of claim ~~6~~¹, wherein the method does not comprise selecting an agent based on its ability to inhibit FKBP-12 rotamase activity.

Claims 8-10 (canceled).

Claim ~~11~~³ (previously presented): The method of claim ~~6~~¹, further comprising determining whether one or more FK506 analogs of interest has the ability to inhibit rotamase activity in order to select an FK506 analog that does not inhibit rotamase activity.

Claims 12-14 (canceled).

Claim ~~15~~⁴ (previously presented): The method of claim ~~6~~¹, wherein the assay for activity in promoting nerve cell growth comprises exposing a cell to the selected FK506 analog and determining if neurite outgrowth is promoted.

Claims 16-19 (canceled).

Claim ⁵20 (previously presented): A method of identifying a FK506 analog that stimulates nerve cell growth, the method comprising:

screening a plurality of FK506 analogs for binding to FKBP-12;

selecting one or more FK506 analogs of interest that has a K_d for FKBP-12 of at least 100 μ M; and

assaying of one or more of the analogs of interest for activity in promoting nerve cell growth.